Dietary advanced glycation end products and risk factors for chronic disease: A systematic review of randomised controlled trials

Nutrients

Volumn 8, Issue 3, 2016, Pages

  Clarke, Rachel E ^a,b   Dordevic, Aimee L ^b   Tan, Sih Min ^a   Ryan, Lisa ^b,c   Coughlan, Melinda T ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Atlantic Technological University   (Ireland)

Author keywords

Advanced glycation end products; Cardiovascular disease; Chronic kidney disease; Diabetes; Diet; Inflammation; Systematic review

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; 8-EPI-PROSTAGLANDIN F2ALPHA; AUTACOID; BIOLOGICAL MARKER; PROSTAGLANDIN F2 ALPHA; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DIABETES MELLITUS; DIETARY INTAKE; GLOMERULUS FILTRATION RATE; GLYCATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATIVE STRESS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WESTERN DIET; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; DIET; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; DIET; DINOPROST; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84960104929     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8030125     Document Type: Review

References (46)

1. Beaglehole, R.; Bonita, R.; Horton, R.; Adams, C.; Alleyne, G.; Asaria, P.; Baugh, V.; Bekedam, H.; Billo, N.; Casswell, S et al. Priority actions for the non-communicable disease crisis. Lancet. 2011, 377, 1438–1447.
2. Kellow, N.J.; Savige, G.S. Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: A systematic review. Eur. J. Clin. Nutr. 2013, 67, 239–248.
3. Van Puyvelde, K.; Mets, T.; Njemini, R.; Beyer, I.; Bautmans, I. Effect of advanced glycation end product intake on inflammation and aging: A systematic review. Nutr. Rev. 2014, 72, 638–650.
4. Feng, J.X.; Hou, F.F.; Liang, M.; Wang, G.B.; Zhang, X.; Li, H.Y.; Xie, D.; Tian, J.W.; Liu, Z.Q. Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model. Kidney Int. 2007, 71, 901–911.
5. Šebeková, K.; Faist, V.; Hofmann, T.; Schinzel, R.; Heidland, A. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am. J. Kidney Dis. 2003, 41, S48–S51.
6. Šebeková, K.; Hofmann, T.; Boor, P.; Ulicná, O.G.; Erbersdobler, H.F.; Baynes, J.W.; Thorpe, S.R.; Heidland, A.; Somoza, V. Renal effects of oral Maillard reaction product load in the form of bread crusts in healthy and subtotally nephrectomized rats. Ann. N. Y. Acad. Sci. 2005, 1043, 482–491.
7. Zheng, F.; He, C.; Cai, W.; Hattori, M.; Steffes, M.; Vlassara, H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 2002, 18, 224–237.
8. Somoza, V.; Lindenmeier, M.; Hofmann, T.; Frank, O.; Erbersdobler, H.F.; Baynes, J.W.; Thorpe, S.R.; Heidland, A.; Zill, H.; Bek, S. et al. Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats. Ann. N. Y. Acad. Sci. 2005, 1043, 492–500.
9. World Health Organisation. Healthy Diet Fact Sheet; World Health Organisation: Geneva, Switzerland, 2015.
10. Dresden University of Technology. AGE Database. Dresden University of Technology, Dresden, Germany, 2012.
11. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4, 1.
12. National Health and Medical Research Council. NHMRC Levels of Evidence and Grades for Recommendations for Guideline Developers, National Health and Medical Research Council, Canberra, Australia, 2009.
13. Higgins, J.P.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928.
14. American Dietetic Association. Evidence Analysis Manual: Steps in the ADA Evidence Analysis Process; American Dietetic Association: Chicago, IL, USA, 2008.
15. Cai, W.; Cijiang, J.; Zhu, L.; Peppa, M.; Lu, C.; Uribarri, J.; Vlassara, H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110, 285–291.
16. Harcourt, B.E.; Sourris, K.C.; Coughlan, M.T.; Walker, K.Z.; Dougherty, S.L.; Andrikopoulos, S.; Morley, A.L.; Thallas-Bonke, V.; Chand, V.; Penfold, S.A. et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011, 80, 190–198.
17. Luévano-Contreras, C.; Garay-Sevilla, M.E.; Wrobel, K.; Malacara, J.M.; Wrobel, K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J. Clin. Biochem. Nutr. 2013, 52, 22–26.
18. Mark, A.B.; Poulsen, M.W.; Andersen, S.; Andersen, J.M.; Bak, M.J.; Ritz, C.; Holst, J.J.; Nielsen, J.; de Courten, B.; Dragsted, L.O. et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014, 37, 88–95.
19. Peppa, M.; Uribarri, J.; Cai, W.; Lu, M.; Vlassara, H. Glycoxidation and inflammation in renal failure patients. Am. J. Kidney Dis. 2004, 43, 690–695.
20. Semba, R.D.; Gebauer, S.K.; Baer, D.J.; Sun, K.; Turner, R.; Silber, H.A.; Talegawkar, S.; Ferrucci, L.; Novotny, J.A. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J. Nutr. 2014, 144, 1037–1042.
21. Uribarri, J.; Cai, W.; Pyzik, R.; Goodman, S.; Chen, X.; Zhu, L.; Ramdas, M.; Striker, G.E.; Vlassara, H. Suppression of native defense mechanisms, SIRT1 and PPAR, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 2014, 46, 301–309.
22. Uribarri, J.; Cai, W.; Ramdas, M.; Goodman, S.; Pyzik, R.; Xue, C.; Zhu, L.; Striker, G.E.; Vlassara, H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 2011, 34, 1610–1616.
23. Uribarri, J.; Peppa, M.; Cai, W.; Goldberg, T.; Lu, M.; Baliga, S.; Vassalotti, J.A.; Vlassara, H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am. J. Kidney Dis. 2003, 42, 532–538.
24. Vlassara, H.; Cai, W.; Crandall, J.; Goldberg, T.; Oberstein, R.; Dardaine, V.; Peppa, M.; Rayfield, E.J. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. USA 2002, 99, 15596–15601.
25. Vlassara, H.; Cai, W.; Goodman, S.; Pyzik, R.; Yong, A.; Chen, X.; Zhu, L.; Neade, T.; Beeri, M.; Silverman, J.M.; et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 2009, 94, 4483–4491.
26. Goldberg, T.; Cai, W.; Peppa, M.; Dardaine, V.; Baliga, B.S.; Uribarri, J.; Vlassara, H. Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc. 2004, 104, 1287–1291.
27. El Nahas, A.M.; Bello, A.K. Chronic kidney disease: The global challenge. Lancet 2005, 365, 331–340.
28. Bierhaus, A.; Schiekofer, S.; Schwaninger, M.; Andrassy, M.; Humpert, P.M.; Chen, J.; Hong, M.; Luther, T.; Henle, T.; Klöting, I. et al. Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-κB. Diabetes 2001, 50, 2792–2808.
29. Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury. Circulation 2006, 114, 597–605.
30. Scheller, J.; Chalaris, A.; Schmidt-Arras, D.; Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813, 878–888.
31. Moller, D.E. Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 2000, 11, 212–217.
32. Basu, S. F2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications. Antioxid. Redox Signal. 2008, 10, 1405–1434.
33. Ceriello, A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 2003, 26, 1589–1596.
34. Forbes, J.M.; Coughlan, M.T.; Cooper, M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes Care 2008, 57, 1446–1454.
35. Seiquer, I.; Rubio, L.A.; Peinado, M.J.; Delgado-Andrade, C.; Navarro, M.P. Maillard reaction products modulate gut microbiota composition in adolescents. Mol. Nutr. Food Res. 2014, 58, 1552–1560.
36. Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet—Induced obesity and diabetes in mice. Diabetes 2008, 57, 1470–1481.
37. Cani, P.D.; Possemiers, S.; Van de Wiele, T.; Guiot, Y.; Everard, A.; Rottier, O.; Geurts, L.; Naslain, D.; Neyrinck, A.; Lambert, D.M. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58, 1091–1103.
38. Coughlan, M.T.; Yap, F.Y.T.; Tong, D.C.K.; Andrikopoulos, S.; Gasser, A.; Thallas-Bonke, V.; Webster, D.E.; Miyazaki, J.; Kay, T.W.; Slattery, R.M. et al. Advanced glycation end products are direct modulators of β-Cell function. Diabetes 2011, 60, 2523–2532.
39. Hofmann, S.M.; Dong, H.-J.; Li, Z.; Cai, W.; Altomonte, J.; Thung, S.N.; Zeng, F.; Fisher, E.A.; Vlassara, H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51, 2082–2089.
40. Sandu, O.; Song, K.; Cai, W.; Zheng, F.; Uribarri, J.; Vlassara, H. Insulin resistance and type 2 diabetes in high-fat–fed mice are linked to high glycotoxin intake. Diabetes 2005, 54, 2314–2319.
41. Birlouez-Aragon, I.; Saavedra, G.; Tessier, F.J.; Galinier, A.; Ait-Ameur, L.; Lacoste, F.; Niamba, C.N.; Alt, N.; Somoza, V.; Lecerf, J.M. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am. J. Clin. Nutr. 2010, 91, 1220–1226.
42. Apple, F.S.; Christenson, R.H.; Danne, O.; Jaffe, A.S.; Mair, J.; Mockel, M.; Pagani, F.; Christenson, R.H.; Mockel, M.; Danne, O. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 2005, 51, 810–824.
43. Tsimikas, S.; Willeit, P.; Willeit, J.; Santer, P.; Mayr, M.; Xu, Q.; Mayr, A.; Witztum, J.L.; Kiechl, S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J. Am. Coll. Cardiol. 2012, 60, 2218–2229.
44. Cerami, C.; Founds, H.; Nicholl, I.; Mitsuhashi, T.; Giordano, D.; Vanpatten, S.; Lee, A.; Al-Abed, Y.; Vlassara, H.; Bucala, R.; Cerami, A. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. USA 1997,94, 13915–13920.
45. Pouillart, P.; Mauprivez, H.; Ait-Ameur, L.; Cayzeele, A.; Lecerf, J.M.; Tessier, F.J.; Birlouez-Aragon, I. Strategy for the study of the health impact of dietary Maillard products in clinical studies: The example of the ICARE clinical study on healthy adults. Ann. N. Y. Acad. Sci. 2008, 1126, 173–176.
46. Ames, J.M. Determination of Nɛ-(Carboxymethyl)lysine in foods and related systems. Ann. N. Y. Acad. Sci. 2008, 1126, 20–24.